For instance, breast cancer cell lines with PIK3CA hotspot mutations show varied responses to PI3K inhibitors, and additional mutations affecting PI3K activity and tumor growth have been identified [11, 18, 40–44]. This evidence concerns the gene PIK3CA and neoplasm.